SIRT is better tolerated than sorafenib, but doesn't increase overall survival in HCC
Results of the SARAH trial presented today demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable hepatocellular ...
Apr 22, 2017
0
2